Axa
ACAD icon

Axa’s Acadia Pharmaceuticals ACAD Stock Holding History

Axa’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,000
Closed -$301K – 1080
2023
Q1 		$301K Buy
+16,000
New +$305K ﹤0.01% 1021
2021
Q2 		– Sell
-75,017
Closed -$1.94M – 1248
2021
Q1 		$1.94M Sell
75,017
-19,596
-21% -$863K 0.01% 854
2020
Q4 		$5.06M Sell
94,613
-61,612
-39% -$3.06M 0.02% 690
2020
Q3 		$6.45M Buy
156,225
+38,904
+33% +$1.68M 0.02% 563
2020
Q2 		$5.69M Buy
117,321
+35,400
+43% +$1.7M 0.02% 580
2020
Q1 		$3.46M Sell
81,921
-68,383
-45% -$2.82M 0.02% 615
2019
Q4 		$6.43M Buy
150,304
+70,104
+87% +$3.05M 0.03% 557
2019
Q3 		$2.89M Buy
+80,200
New +$2.43M 0.01% 791
2017
Q3 		– Sell
-61,875
Closed -$1.73M – 1307
2017
Q2 		$1.73M Sell
61,875
-102,639
-62% -$3.06M 0.01% 812
2017
Q1 		$5.66M Sell
164,514
-5,061
-3% -$179K 0.03% 574
2016
Q4 		$4.89M Buy
169,575
+3,236
+2% +$85.6K 0.02% 588
2016
Q3 		$5.29M Buy
166,339
+95
+0.1% +$3.22K 0.02% 559
2016
Q2 		$5.4M Sell
166,244
-149,938
-47% -$5.02M 0.02% 550
2016
Q1 		$8.84M Sell
316,182
-5,108
-2% -$111K 0.04% 418
2015
Q4 		$11.5M Sell
321,290
-6,753
-2% -$238K 0.05% 353
2015
Q3 		$10.8M Buy
328,043
+163,315
+99% +$6.79M 0.04% 360
2015
Q2 		$6.9M Hold
164,728
– – 0.03% 503
2015
Q1 		$5.37M Buy
164,728
+119,277
+262% +$4.1M 0.02% 577
2014
Q4 		$1.44M Buy
45,451
+2,908
+7% +$82.5K 0.01% 877
2014
Q3 		$1.05M Sell
42,543
-273
-0.6% -$6.38K ﹤0.01% 896
2014
Q2 		$967K Sell
42,816
-1,722
-4% -$36K ﹤0.01% 936
2014
Q1 		$1.08M Buy
44,538
+2,319
+5% +$58.7K ﹤0.01% 905
2013
Q4 		$1.05M Buy
+42,219
New +$996K ﹤0.01% 912

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Axa's ACAD Position: Q2 2023 in Review

Axa sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 16,000 shares — an estimated $301K sold.

Axa first reported a position in ACAD in Q4 2013 and held it in 23 quarters. The position peaked at $11.5M in Q4 2015. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

  • Axa reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Axa sold 16,000 Acadia Pharmaceuticals shares in Q2 2023, an estimated $301K.
  • Axa first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 23 quarters.
  • Axa's Acadia Pharmaceuticals position peaked at $11.5M in Q4 2015.
  • 236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.